Unlock instant, AI-driven research and patent intelligence for your innovation.

Macrocyclic derivatives as protein kinase inhibitors and their preparation and use

A kind of use and drug technology, applied in the field of disease drugs, macrocyclic derivatives and their preparation, can solve the problems of high incidence of adverse reactions, low bioavailability, large dosage, etc., and achieve good clinical application and medicine The effect of use

Active Publication Date: 2021-10-01
WUHAN YUXIANG PHARM TECH CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The technical problem to be solved by the present invention is to overcome the deficiencies of existing drugs and prior art, thereby providing a macrocyclic derivative as a protein kinase inhibitor. As an ALK inhibitor, this compound can effectively solve the problem of prior art Problems of large dosage, low bioavailability, and high incidence of adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Macrocyclic derivatives as protein kinase inhibitors and their preparation and use
  • Macrocyclic derivatives as protein kinase inhibitors and their preparation and use
  • Macrocyclic derivatives as protein kinase inhibitors and their preparation and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Embodiment 1: compound shown in synthetic formula I-1

[0058] synthetic route:

[0059]

[0060] Preparation:

[0061] Step 1: Synthesis of Compound 1B

[0062] In the first reaction vessel, to a solution of cooled (0 °C) water (3.5 mL) was added SOC1 2 (0.642 mL, 1.64 g / mL, 8.84 mmol) and allowed to warm to room temperature and stir for 1 hour. Then cuprous chloride (19mg, 0.20mmol) was added, and the solution was cooled to -5°C to obtain the first mixed solution. In a second reaction vessel, dissolve in HCl (1.97 mL, 37% in H 2 O, 1.18g / mL, 23.6mmol) solution was added compound 1A (500mg, 2.5mmol) (synthetic reference patent WO2015050989A1), and cooled to -5 ° C, then sodium nitrite (149mg, 2.16mmol) in water ( 1 mL) solution was added thereto to obtain a second mixed solution. Then the second mixed solution was added dropwise to the first mixed solution, and kept at -5°C by cooling. After the dropwise addition was completed, the third mixed solution was ob...

Embodiment 2

[0083] Embodiment 2: compound shown in synthetic formula I-2

[0084]

[0085] The compound of Example 2 was synthesized with reference to the operation steps of Example 1, but methylamine hydrochloride was replaced with ethylamine hydrochloride in the second step.

[0086] MS m / z(ESI):471[M+1]

[0087] 1 H NMR (400MHz, CDCl 3 )δ7.84(d, 1H, J=2.0Hz), 7.32(dd, 1H, J=9.6, 2.4Hz), 7.23(dd, 1H, J=8.0, 5.2Hz), 7.01(dt, 1H, J =8.4,2.4Hz),6.86(d,1H,J=1.6Hz),5.71-5.75(m,1H),4.85(s,2H),4.08(s,3H),3.24(m,2H),1.78 (d, 3H, J=6.4Hz), 1.19 (t, 3H, J=6.90Hz).

Embodiment 3

[0088] Embodiment 3: compound shown in synthetic formula I-3

[0089]

[0090] The compound of Example 3 was synthesized with reference to the operation steps of Example 1, but in the first step, it was replaced with 3-amino-4-bromo-1-ethyl-1H-pyrazole-5-carbonitrile (synthetic reference patent WO2015050989A1) 3-Amino-4-bromo-1-methyl-1H-pyrazole-5-carbonitrile was dropped.

[0091] MS m / z(ESI):471[M+1]

[0092] 1 H NMR (400MHz, CDCl 3 )δ7.85 (d, 1H, J = 2.0Hz), 7.31 (dd, 1H, J = 9.6, 2.4Hz), 7.22 (dd, 1H, J = 8.4, 5.6Hz), 6.98 (dt, 1H, J =8.0,2.8Hz),6.87(d,1H,J=1.2Hz),5.71-5.75(m,1H),4.85(s,2H),4.12(q,2H,J=7.2Hz),3.24(s , 3H), 1.78 (d, 3H, J=6.0Hz), 1.28 (t, 3H, J=7.1Hz).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a macrocyclic derivative as a protein kinase inhibitor, a preparation method and an application thereof. The present invention provides a compound as shown in formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, wherein R 1 ~R 4 as defined in the specification. The compound represented by formula I of the present invention can be used to prepare medicines for regulating protein kinase activity and preventing and / or treating diseases related to protein kinases.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a macrocyclic derivative as a protein kinase inhibitor, a preparation method and application thereof. Specifically, the present invention relates to macrocyclic derivatives as protein kinase inhibitors, their preparation methods, and their use in the preparation of drugs for the prevention and / or treatment of ALK-related diseases. Background technique [0002] Malignant tumor is a common and frequently-occurring disease that seriously threatens human health. It is characterized by abnormal proliferation of cells or mutant cells. The proliferation, apoptosis, and metastasis of tumor cells are closely related to the abnormality of a certain link in a series of signal transduction pathways inside and outside the cells. In these signaling pathways, an important class of molecules is protein kinases. The abnormality of protein kinases is closely related to the occurrence, developme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D515/18A61K31/439A61P35/00
CPCA61P35/00C07B2200/07C07D515/18
Inventor 方华祥余斌李芳芳张晓林车鹏许勇
Owner WUHAN YUXIANG PHARM TECH CO LTD